The KANK1 Knockout NCI-H1975 Polyclonal Cells comprise a heterogeneous population of NCI-H1975 cells that have undergone CRISPR/Cas9-mediated disruption of the KANK1 gene, creating a versatile loss-of-function model for studying cytoskeletal regulation and cell migration. The polyclonal format captures a broad spectrum of genetic alterations, avoiding clonal selection bias and providing a robust platform for phenotypic assays. This product is supplied as a live cell population and is ready for expansion and downstream functional experiments.
NCI-H1975 is a human lung adenocarcinoma cell line with epithelial morphology, established from a non-small cell lung cancer (NSCLC) patient. These cells harbor clinically relevant mutations, including EGFR T790M and L858R, making them a widely used model for oncogenic signaling and drug resistance research. Their adherent growth, stable epithelial characteristics, and well-documented genetic background facilitate reproducible cell-based studies of NSCLC biology, including proliferation, apoptosis, and metastatic progression.
KANK1 encodes a scaffold protein that is essential for coordinating focal adhesion dynamics and actin cytoskeleton organization. Upon integrin engagement and RhoA activation, KANK1 simultaneously binds talin and liprin-beta1, recruiting liprin-beta1 to nascent adhesions and promoting actin polymerization. This scaffolding function stabilizes the talin-integrin-actin linkage, enabling proper focal adhesion turnover. Loss of KANK1 disrupts these complexes, impairing focal adhesion maturation and leading to enhanced cell motility. Thus, KANK1 operates at the interface of Rho GTPase signaling, integrin activation, and actin filament assembly, integrating extracellular matrix cues to control cell-ECM interactions.
In the context of NSCLC, KANK1 is thought to act as a tumor suppressor, with diminished expression associated with increased metastatic capacity. The KANK1 Knockout NCI-H1975 Polyclonal Cells therefore offer a powerful tool to dissect the molecular mechanisms by which KANK1 loss contributes to invasive phenotypes. Researchers can examine how the absence of this scaffold protein alters focal adhesion composition, RhoA signaling, and cytoskeletal reorganization, thereby providing insights into pathways that drive lung cancer progression and metastasis.
These knockout cells are suitable for a range of targeted assays, including transwell migration and wound healing assays to quantify enhanced motility, as well as western blotting for focal adhesion proteins such as talin and liprin-beta1. Immunofluorescence staining of F-actin and vinculin permits visualization of adhesion complex remodeling, while RhoA activation assays elucidate altered GTPase signaling. The model also supports drug response screening to assess how KANK1 loss modulates sensitivity to cytoskeletal inhibitors or targeted therapies. For further information or to request a quote, please contact Ascent Research.
